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Background
Adrenoleukodystrophy (ALD) is an X-linked genetic
condition. This causes an inability to break down very
long chain fatty acids (VLCFAs). VLCFA buildup
damages myelin sheath on nerves. This can lead to
severe neurological function loss and can lead to
adrenomyeloneuropathy (AMN), a slowly progressive
spinal cord disease. AMN largely impacts males from
30-40 years old and post-menopausal women.

35%-45% of males with ALD suffer from Cerebral ALD
(CALD). In CALD, individuals between 3-10 years old
suffer from rapid inflammatory cerebral
demyelination. Notable symptoms are loss of senses
and coordination, general illness, and a loss of
neurological function. Untreated, CALD often leads to
death.

Statistics
Impacts 1 in 14,700
individuals

With early treatment,
about 94% survival
from CALD

•

The pathognomonic accumulation of straight chain, saturated VLCFAs (i.e.,
made up of more than 22 carbon atoms) is the hallmark of this disease.
• The accumulation of VLCFAs is the result of an abnormality in their
degradation.
• Reduced activity of the enzyme VLCS that activates VLCFAs to their CoA
derivatives, the substrate for the β-oxidation cycle in peroxisomes, results
in pathognomonic accumulation of VLCFAs in tissues such as the adrenals,
testes, and brain in X-ALD patients.
• Consequently, they are the cause of the metabolic disease in X-ALD.

Hematopoietic Stem Cell Transplantation (HSCT): reported stabilization
(and possibly reversal) of neurological changes that persists for five to
ten years (Moser, 2012)

•

Other Therapeutic Explorations

•

•

•

80% of males suffer
adrenal insufficiency
leading to Addison’s
disease

Of males with AMN,
about 20% develop
cerebral disease leading
to disability and death

A Therapeutic Targeting the
Alteration

•

ALD can be diagnosed at birth, but the clinical course cannot be
predicted. Patients are pre-symptomatic at birth.
ALD research should investigate if an increase in MCP-1 or chitotriosidase
occurs before, or as a consequence of, the neuroinflammation and
damage to the BBB during the onset of cerebral ALD, and if they could be
an early predictive biomarker for cerebral ALD.
In addition, as shown in Alzheimer’s disease clinical trials targeting
neuroinflammation , chitotriosidase and perhaps MCP-1 could serve as
pharmacodynamic markers of neuroinflammation, specifically microglial
activation, which would be relevant for use in cerebral ALD clinical trials.
NfL may be suitable as a general dynamic marker of neuro-axonal injury
for ALD, with longitudinal measurements being used to monitor disease
activity and response to treatment in ALD clinical trials.
For example, NfL levels in the blood will be affected by peripheral
neuropathy, in addition to factors such as an individual’s body mass index
or blood volume.

Hormone replacement
therapy

Dietary therapy with
Lorenzo oil

Mandatory for all X-ALD patients who
have primary adrenocortical
insufficiency (Moser, 2012)

Oral administration of this oil, with
reduction of fat, significantly lowers the
levels of VLCFA in the plasma of patients
within four weeks. (Moser, 2012)
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